Literature DB >> 32333165

Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors.

Elina Misicka1, Corriene Sept1, Farren B S Briggs2.   

Abstract

BACKGROUND: Predicting the transition from relapsing-remitting (RR) to secondary-progressive (SP) multiple sclerosis (MS) from early in the disease course is challenging.
OBJECTIVE: To construct prediction models for SPMS using sociodemographic and self-reported clinical measures that would be available at/near MS onset, with specific considerations for MS genetic risk factors.
METHODS: We conducted a retrospective cross-sectional study based on 1295 white, non-Hispanic individuals. Cox proportional hazard prediction models were generated for three censored SPMS outcomes (ever transitioning, transitioning within 10 years, and transitioning within 20 years) using sociodemographic, comorbid health information, symptomatology, and other measures of early disease activity. HLADRB1*15:01 and HLA-A*02:01, as well as a genetic risk score, were iteratively considered in each model. We also explored the relationships for all 200 MS risk variants located outside the major histocompatibility complex. Nomograms were generated for the final prediction models.
RESULTS: An older age of MS onset and being male predicted a short latency to SPMS, while a longer interval between the first two relapses predicted a much longer latency. Comorbid conditions and onset symptomatology variably predicted the risk for transitioning to SPMS for each censored outcome. The most notable observation was that HLA-A*02:01, which confers decreased risk for MS, also contributed to decreased hazards for SPMS.
CONCLUSIONS: These results have the potential to advance prognostication for a person with MS using information available at or near onset, potentially improving care and quality of life for those who live with MS.

Entities:  

Keywords:  Multiple sclerosis; Prognostics; Risk prediction; Secondary progressive

Mesh:

Year:  2020        PMID: 32333165     DOI: 10.1007/s00415-020-09850-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  54 in total

1.  Impact of multiple sclerosis relapses on progression diminishes with time.

Authors:  H Tremlett; M Yousefi; V Devonshire; P Rieckmann; Y Zhao
Journal:  Neurology       Date:  2009-11-04       Impact factor: 9.910

Review 2.  Functional clinical outcomes in multiple sclerosis: Current status and future prospects.

Authors:  Rana Karabudak; Maurice Dahdaleh; Mohammed Aljumah; Raed Alroughani; I Ahmed Alsharoqi; Abdulrahman M AlTahan; Saeed A Bohlega; Abdulkader Daif; Dirk Deleu; Amer Amous; Jihad S Inshasi; Peter Rieckmann; Mohammed A Sahraian; Bassem I Yamout
Journal:  Mult Scler Relat Disord       Date:  2015-03-23       Impact factor: 4.339

3.  Estimating the prevalence of multiple sclerosis using 56.6 million electronic health records from the United States.

Authors:  Farren Bs Briggs; Eddie Hill
Journal:  Mult Scler       Date:  2019-07-24       Impact factor: 6.312

Review 4.  The clinical course of multiple sclerosis.

Authors:  Christian Confavreux; Sandra Vukusic
Journal:  Handb Clin Neurol       Date:  2014

Review 5.  Sex-related factors in multiple sclerosis susceptibility and progression.

Authors:  Rhonda R Voskuhl; Stefan M Gold
Journal:  Nat Rev Neurol       Date:  2012-03-27       Impact factor: 42.937

6.  Predicting risk of secondary progression in multiple sclerosis: A nomogram.

Authors:  Ali Manouchehrinia; Feng Zhu; Daniela Piani-Meier; Markus Lange; Diego G Silva; Robert Carruthers; Anna Glaser; Elaine Kingwell; Helen Tremlett; Jan Hillert
Journal:  Mult Scler       Date:  2018-06-18       Impact factor: 6.312

7.  The natural history of secondary progressive multiple sclerosis.

Authors:  Marcus Koch; Elaine Kingwell; Peter Rieckmann; Helen Tremlett
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-07-16       Impact factor: 10.154

8.  Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies.

Authors:  Francisco Coret; Francisco C Pérez-Miralles; Francisco Gascón; Carmen Alcalá; Arantxa Navarré; Ana Bernad; Isabel Boscá; Matilde Escutia; Sara Gil-Perotin; Bonaventura Casanova
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-06-26

9.  The prevalence of MS in the United States: A population-based estimate using health claims data.

Authors:  Mitchell T Wallin; William J Culpepper; Jonathan D Campbell; Lorene M Nelson; Annette Langer-Gould; Ruth Ann Marrie; Gary R Cutter; Wendy E Kaye; Laurie Wagner; Helen Tremlett; Stephen L Buka; Piyameth Dilokthornsakul; Barbara Topol; Lie H Chen; Nicholas G LaRocca
Journal:  Neurology       Date:  2019-02-15       Impact factor: 9.910

10.  Defining the clinical course of multiple sclerosis: the 2013 revisions.

Authors:  Fred D Lublin; Stephen C Reingold; Jeffrey A Cohen; Gary R Cutter; Per Soelberg Sørensen; Alan J Thompson; Jerry S Wolinsky; Laura J Balcer; Brenda Banwell; Frederik Barkhof; Bruce Bebo; Peter A Calabresi; Michel Clanet; Giancarlo Comi; Robert J Fox; Mark S Freedman; Andrew D Goodman; Matilde Inglese; Ludwig Kappos; Bernd C Kieseier; John A Lincoln; Catherine Lubetzki; Aaron E Miller; Xavier Montalban; Paul W O'Connor; John Petkau; Carlo Pozzilli; Richard A Rudick; Maria Pia Sormani; Olaf Stüve; Emmanuelle Waubant; Chris H Polman
Journal:  Neurology       Date:  2014-05-28       Impact factor: 9.910

View more
  1 in total

1.  Liver kinase B1 rs9282860 polymorphism and risk for multiple sclerosis in White and Black Americans.

Authors:  Anne I Boullerne; Mitchell T Wallin; William J Culpepper; Heidi Maloni; Elizabeth A Boots; Dagmar M Sweeney; Douglas L Feinstein
Journal:  Mult Scler Relat Disord       Date:  2021-08-02       Impact factor: 4.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.